Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Michail Kalfas, Rosie H. Taylor, Dimosthenis Tsapekos & Allan H. Young. (2023) Psychedelics for treatment resistant depression: are they game changers?. Expert Opinion on Pharmacotherapy 0:0, pages 1-16.
Read now
Read now
Raman Sharma, Rachel Batchelor & Jacqueline Sin. (2023) Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. Journal of Psychoactive Drugs 55:5, pages 612-630.
Read now
Read now
Ricardo Jorge Dinis-Oliveira. (2017) Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metabolism Reviews 49:1, pages 84-91.
Read now
Read now
Articles from other publishers (48)
María Marcela Velásquez Toledo. (2023) Evidencias y perspectivas del potencial antidepresivo del “alcaloide mágico” psilocibina: una revisión narrativa. Cultura y Droga 28:35, pages 91-113.
Crossref
Crossref
Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, Alessandro Serretti & Chiara Fabbri. (2023) Clinical specificity profile for novel rapid acting antidepressant drugs. International Clinical Psychopharmacology 38:5, pages 297-328.
Crossref
Crossref
Marco Pepe, Mohsen Hesami, Karla A. de la Cerda, Melissa L. Perreault, Tom Hsiang & Andrew Maxwell Phineas Jones. (2023) A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond. Biotechnology Advances, pages 108247.
Crossref
Crossref
Rabeet Tariq. (2023) Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and
Potential Harms. Current Reviews in Clinical and Experimental Pharmacology 18:2, pages 94-109.
Crossref
Crossref
F. Benvenuti, D. Colombo, L. Soverchia, N. Cannella, E. Domi & R. Ciccocioppo. (2023) Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories. Psychopharmacology 240:7, pages 1521-1530.
Crossref
Crossref
Lana Strika-Bruneau, Baptiste Fauvel, David Dupuis & Amine Benyamina. (2023) Articulation de la thérapie d’acceptation et d’engagement à la psychothérapie assistée par psychédéliques en addictologie. L'Évolution Psychiatrique 88:2, pages 284-298.
Crossref
Crossref
Jing Wang, Min Liang, Qing Shang, Hongyan Qian, Ran An, Hua Liu, Gaojie Shao, Tao Li & Xinshe Liu. (2023)
Psilocin suppresses methamphetamine‐induced hyperlocomotion and acquisition of conditioned place preference via
D2R
‐mediated
ERK
signaling
. CNS Neuroscience & Therapeutics 29:3, pages 831-841.
Crossref
Crossref
Mason Marks. (2023) The varieties of psychedelic law. Neuropharmacology 226, pages 109399.
Crossref
Crossref
Megan Pedicini & Zachary A. Cordner. (2023) Utility of preclinical models in the study of psilocybin – A comprehensive review. Neuroscience & Biobehavioral Reviews 146, pages 105046.
Crossref
Crossref
Deborah Rudin, Alexander Areesanan, Matthias E. Liechti & Carsten Gründemann. (2023) Classic psychedelics do not affect T cell and monocyte immune responses. Frontiers in Psychiatry 14.
Crossref
Crossref
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, Giulia Abate, Sara Anna Bonini, Gregorio Peron, Emanuela Tirelli, Mariachiara Pucci, Giovanni Ribaudo, Erika Oselladore, Marika Premoli, Alessandra Gianoncelli, Daniela Letizia Uberti & Maurizio Memo. (2023) The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. International Journal of Molecular Sciences 24:2, pages 1329.
Crossref
Crossref
David R. Maguire. (2023) Effects of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-Quinoline (Quipazine) on Fentanyl Versus Food Choice in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics 384:1, pages 155-162.
Crossref
Crossref
Amza Ali, Mary-Elizabeth Gifford, Henry Lowe, Lorenzo Gordon & Justin Grant. 2023. Mushrooms with Therapeutic Potentials. Mushrooms with Therapeutic Potentials
479
492
.
David M. O’Shaughnessy, Zoltán Sarnyai, Frances Quirk & Robin Rodd. (2022) Traditional Amazonian medicine in addiction treatment: Qualitative results. SSM - Qualitative Research in Health 2, pages 100086.
Crossref
Crossref
Javier Calleja‐Conde, Jose Angel Morales‐García, Víctor Echeverry‐Alzate, Kora Mareen Bühler, Elena Giné & Jose Antonio López‐Moreno. (2022) Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies. Addiction Biology 27:6.
Crossref
Crossref
Dev B Goel & Sarju Zilate. (2022) Potential Therapeutic Effects of Psilocybin: A Systematic Review. Cureus.
Crossref
Crossref
Mathias Ebbesen Jensen, Dea Siggaard Stenbæk, Tobias Søgaard Juul, Patrick MacDonald Fisher, Claus Thorn Ekstrøm, Gitte Moos Knudsen & Anders Fink-Jensen. (2022) Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). BMJ Open 12:10, pages e066019.
Crossref
Crossref
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, Gabriela Morales-Lima, João Ariel Bonar Fernandes & Renato Filev. (2022) Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neuroscience 3, pages 100025.
Crossref
Crossref
George Winter. (2022) Psilocybin administration. Journal of Prescribing Practice 4:8, pages 340-341.
Crossref
Crossref
Dina Fradkin. (2021) Psilocybin: A brief overview for psychiatric mental health nurse practitioners. Perspectives in Psychiatric Care 58:3, pages 1200-1203.
Crossref
Crossref
V. L. Matrenitsky. (2022) РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ. Likarska sprava:3-4, pages 37-59.
Crossref
Crossref
Nataliya Vorobyeva & Alena A. Kozlova. (2022) Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. Frontiers in Pharmacology 13.
Crossref
Crossref
Curro Polo-Castellano, José Á. Álvarez, Miguel Palma, Gerardo F. Barbero, Jesús Ayuso & Marta Ferreiro-González. (2022) Optimization through a Box–Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (Psylocibe cubensis). Journal of Fungi 8:6, pages 598.
Crossref
Crossref
Dimitri Daldegan-Bueno, Lucas Oliveira Maia, Carolina Marcolino Massarentti & Luís Fernando Tófoli. (2022) Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil. Psychopharmacology 239:6, pages 1767-1782.
Crossref
Crossref
Katharina Dworatzyk, Tallulah Jansen & Timo Torsten Schmidt. (2022) Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI). PLOS ONE 17:3, pages e0264927.
Crossref
Crossref
Maria Bălăeţ. (2022) Psychedelic Cognition—The Unreached Frontier of Psychedelic Science. Frontiers in Neuroscience 16.
Crossref
Crossref
David Dupuis. (2022) The psychedelic ritual as a technique of the self. HAU: Journal of Ethnographic Theory 12:1, pages 198-216.
Crossref
Crossref
Shawn Ziff, Benjamin Stern, Gregory Lewis, Maliha Majeed & Vasavi Rakesh Gorantla. (2022) Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. Cureus.
Crossref
Crossref
IIana Berlowitz. (2022) Plantes psychotropes, médecines traditionnelles autochtones du Pérou et renaissance
psychédélique. Drogues, santé et société 20:1, pages 90-116.
Crossref
Crossref
Yoosuk An, Seon Young Park & Ung Gu Kang. (2022) “Drugs of Abuse” as a “New Antidepressant”: - A Review on Pharmacological Mechanisms, Antidepressant Effects, and Abuse Potential. Journal of Korean Neuropsychiatric Association 61:4, pages 243.
Crossref
Crossref
Chia-Ling Yu, Fu-Chi Yang, Szu-Nian Yang, Ping-Tao Tseng, Brendon Stubbs, Ta-Chuan Yeh, Chih-Wei Hsu, Dian-Jeng Li & Chih-Sung Liang. (2021) Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis. Psychiatry Investigation 18:10, pages 958-967.
Crossref
Crossref
William M. Meil, William Farrell & Reem Satti. 2021. Addictions - Diagnosis and Treatment. Addictions - Diagnosis and Treatment.
Mason Marks & I. Glenn Cohen. (2021) Psychedelic therapy: a roadmap for wider acceptance and utilization. Nature Medicine 27:10, pages 1669-1671.
Crossref
Crossref
Henry Lowe, Ngeh Toyang, Blair Steele, Henkel Valentine, Justin Grant, Amza Ali, Wilfred Ngwa & Lorenzo Gordon. (2021) The Therapeutic Potential of Psilocybin. Molecules 26:10, pages 2948.
Crossref
Crossref
Elyes Dahmane, Paul R. Hutson & Jogarao V. S. Gobburu. (2020) Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Psilocybin/Psilocin. Clinical Pharmacology in Drug Development 10:1, pages 78-85.
Crossref
Crossref
Alec J. DiVito & Robert F. Leger. (2020) Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. Molecular Biology Reports 47:12, pages 9791-9799.
Crossref
Crossref
David Dupuis. (2020) Le rite hallucinogène comme technique du Soi : une approche anthropologique de l’efficacité des psychédéliques dans le traitement des addictions. Psychotropes Vol. 26:1, pages 35-59.
Crossref
Crossref
Philip Brenner, Lena Brandt, Gang Li, Allitia DiBernardo, Robert Bodén & Johan Reutfors. (2019) Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study. Addiction 115:4, pages 768-777.
Crossref
Crossref
Kristin Heuschkel & Kim P.C. Kuypers. (2020) Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Frontiers in Psychiatry 11.
Crossref
Crossref
Uttam Garg, Jeff Knoblauch, C. Clinton FrazeeIIIIII, Adrian Baron & Mary Dudley. 2020. Toxicology Cases for the Clinical and Forensic Laboratory. Toxicology Cases for the Clinical and Forensic Laboratory
379
382
.
John Gardner, Adrian Carter, Kerry O’Brien & Kate Seear. (2019) Psychedelic-assisted therapies: The past, and the need to move forward responsibly. International Journal of Drug Policy 70, pages 94-98.
Crossref
Crossref
Kevin Sean Murnane. (2019) Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder. Behavioural Pharmacology 30:2 and 3, pages 151-162.
Crossref
Crossref
Amitava Dasgupta. 2019. Critical Issues in Alcohol and Drugs of Abuse Testing. Critical Issues in Alcohol and Drugs of Abuse Testing
477
494
.
Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks & Jack E. Henningfield. (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142, pages 143-166.
Crossref
Crossref
Mohammed Akbar, Mark Egli, Young-Eun Cho, Byoung-Joon Song & Antonio Noronha. (2018) Medications for alcohol use disorders: An overview. Pharmacology & Therapeutics 185, pages 64-85.
Crossref
Crossref
Kevin S. Murnane. 2018. Psychedelic Neuroscience. Psychedelic Neuroscience
25
67
.
Joseph P. Barsuglia, Martin Polanco, Robert Palmer, Benjamin J. Malcolm, Benjamin Kelmendi & Tanya Calvey. 2018. Psychedelic Neuroscience. Psychedelic Neuroscience
121
158
.
Mason Marks. (2022) The Varieties of Psychedelic Law. SSRN Electronic Journal.
Crossref
Crossref